Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis

Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offe...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nanomedicine Ročník 13; číslo 7; s. 2251 - 2262
Hlavní autori:	Jain, Anjali, Pooladanda, Venkatesh, Bulbake, Upendra, Doppalapudi, Sindhu, Rafeeqi, Towseef Amin, Godugu, Chandraiah, Khan, Wahid
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Elsevier Inc 01.10.2017
Predmet:	Administration, Topical Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - pharmacokinetics Anti-Inflammatory Agents - therapeutic use Benzoquinones - administration & dosage Benzoquinones - pharmacokinetics Benzoquinones - therapeutic use Imiquimod induced psoriatic plaque model Inflammation Interleukin-17 - analysis Interleukin-2 - analysis Interleukin-6 - analysis Internal Medicine Liposomes Lipospheres Male Mice Mice, Inbred BALB C Psoriasis Psoriasis - drug therapy RAW 264.7 Cells Skin - drug effects Skin - pathology Skin Absorption Thymoquinone Tumor Necrosis Factor-alpha - analysis Inflammation Psoriasis Lipospheres Thymoquinone Imiquimod induced psoriatic plaque model Imiquimod induced psoriatic mice model
ISSN:	1549-9634, 1549-9642, 1549-9642
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Anti-inflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1β, TNF-α, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-α in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis. Present work explores the potential of TMQ lipospheres in the treatment of psoriasis. TMQ loaded lipospheres were prepared and characterized for suitability in TMQ topical delivery. In vitro and in vivo studies were performed to determine the anti-inflammatory and anti-psoriatic activity of these lipospheres. Results suggest the potential of TMQ lipospheres in the management of psoriasis. [Display omitted]
AbstractList	Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Anti-inflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1β, TNF-α, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-α in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis. Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Anti-inflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1β, TNF-α, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-α in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis. Present work explores the potential of TMQ lipospheres in the treatment of psoriasis. TMQ loaded lipospheres were prepared and characterized for suitability in TMQ topical delivery. In vitro and in vivo studies were performed to determine the anti-inflammatory and anti-psoriatic activity of these lipospheres. Results suggest the potential of TMQ lipospheres in the management of psoriasis. [Display omitted] Abstract Thymoquinone (TMQ) is reported with good anti-psoriatic activity however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offer an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Anti-inflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1β, TNF-α, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-α in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis. Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Anti-inflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1β, TNF-α, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-α in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis.Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ hinder its delivery to target site. To address these delivery challenges of TMQ, lipospheres were explored. The topical use of lipospheres offers an effective mean of penetration along with stability and scalability. TMQ lipospheres of particle size below 70 nm were prepared and evaluated. These lipospheres resulted in deeper skin penetration, slow release and skin compatibility. Anti-inflammatory and anti-psoriatic potential of lipospheres was determined using in vitro cell lines and imiquimod induced psoriatic plaque model. Cell lines studies indicated reduction in the level of nitric oxide and IL-2, IL-6, IL-1β, TNF-α, whereas in vivo results indicated improvement in the phenotypic, histopathological features and reduced level of IL-17 and TNF-α in psoriatic skin. These results suggest the potential of TMQ lipospheres in the management of psoriasis.
Author	Bulbake, Upendra Khan, Wahid Pooladanda, Venkatesh Godugu, Chandraiah Doppalapudi, Sindhu Rafeeqi, Towseef Amin Jain, Anjali
Author_xml	– sequence: 1 givenname: Anjali surname: Jain fullname: Jain, Anjali organization: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India – sequence: 2 givenname: Venkatesh surname: Pooladanda fullname: Pooladanda, Venkatesh organization: Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India – sequence: 3 givenname: Upendra surname: Bulbake fullname: Bulbake, Upendra organization: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India – sequence: 4 givenname: Sindhu surname: Doppalapudi fullname: Doppalapudi, Sindhu organization: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India – sequence: 5 givenname: Towseef Amin surname: Rafeeqi fullname: Rafeeqi, Towseef Amin organization: Regional Research Institute of Unani Medicine, University of Kashmir campus, Srinagar, India – sequence: 6 givenname: Chandraiah surname: Godugu fullname: Godugu, Chandraiah organization: Department of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India – sequence: 7 givenname: Wahid surname: Khan fullname: Khan, Wahid email: wahid@niperhyd.ac.in, mail4wahid@gmail.com organization: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28647592$$D View this record in MEDLINE/PubMed
BookMark	eNqFkl9rHCEUxaWkNH_aL9CHMo992ak6rjuWUgihSQMLgbR9Flev5G5ndKpuYL99HTbNQyDpkwq_c7z33HtKjkIMQMh7RltGmfy0bYMJseWUrVoqW0rVK3LClkItlBT86PHeiWNymvOW0m5VoTfkmPdSrJaKn5DbNU4xT3eQoBnBoSngmhIntGZoHAx4D2nfRN-Uu_0Y_-xwrqHBUN_QlASmjBDKDEw5JjQZ81vy2pshw7uH84z8uvz28-L7Yn1zdX1xvl5YIXlZCBAb4N44SntOpWEgXcf9BqSinVn2znlvlXJuw7ntBfecS9V7AZYpxx3vzsjHg--UamGQix4xWxgGEyDusmaKdX1X3VlFPzygu03tUk8JR5P2-l8OFeAHwKaYcwL_iDCq57D1Vs9h6zlsTaWuOVZR_0RksZiCMZRkcHhZ-uUghRrQPULS2SIEWyeQwBbtIr4s__pEbgcM88x-wx7yNu5SqNFrpjPXVP-YF2HeA7bqKGOyrwafnzf43-9_AYh7xCU
CitedBy_id	crossref_primary_10_1007_s12013_024_01595_0 crossref_primary_10_1016_j_fct_2022_113260 crossref_primary_10_1016_j_jddst_2023_105088 crossref_primary_10_1016_j_jddst_2020_101838 crossref_primary_10_1111_jdv_16725 crossref_primary_10_1016_j_chemphyslip_2018_11_009 crossref_primary_10_1080_10717544_2020_1754527 crossref_primary_10_1016_j_jddst_2019_05_041 crossref_primary_10_1208_s12249_025_03074_y crossref_primary_10_1016_j_ijpharm_2019_118726 crossref_primary_10_2174_1574885514666190212113754 crossref_primary_10_1038_s41419_018_1247_9 crossref_primary_10_1016_j_jddst_2022_103301 crossref_primary_10_3390_gels9020112 crossref_primary_10_1016_j_addr_2018_03_010 crossref_primary_10_1080_03639045_2019_1576722 crossref_primary_10_3389_fphar_2021_644952 crossref_primary_10_1016_j_eujim_2022_102154 crossref_primary_10_1016_j_jddst_2025_107492 crossref_primary_10_3390_ijms232415980 crossref_primary_10_1016_j_jddst_2025_107293 crossref_primary_10_1186_s12951_025_03660_z crossref_primary_10_3390_jfb14010019 crossref_primary_10_1016_j_ejphar_2023_175668 crossref_primary_10_1016_j_ijpharm_2021_120536 crossref_primary_10_1016_j_jddst_2020_101691 crossref_primary_10_1016_j_jddst_2021_102364 crossref_primary_10_2217_nnm_2018_0397 crossref_primary_10_1111_dth_13113 crossref_primary_10_3390_pharmaceutics12060567 crossref_primary_10_1016_j_nano_2019_02_018 crossref_primary_10_1208_s12249_019_1468_y crossref_primary_10_1007_s13346_020_00723_6 crossref_primary_10_1016_j_jsps_2019_09_008 crossref_primary_10_3390_pharmaceutics14071449 crossref_primary_10_1007_s40005_024_00697_4 crossref_primary_10_1016_j_tiv_2018_05_010 crossref_primary_10_1002_ptr_6344 crossref_primary_10_1208_s12249_020_01831_9 crossref_primary_10_1208_s12249_022_02482_8 crossref_primary_10_1080_10837450_2020_1765378 crossref_primary_10_1016_j_intimp_2019_03_035 crossref_primary_10_3389_fonc_2022_1092020 crossref_primary_10_3390_nu10101369 crossref_primary_10_3390_ph14040369 crossref_primary_10_1080_03639045_2020_1820031 crossref_primary_10_1016_j_ijpharm_2018_08_024 crossref_primary_10_3390_gels8110733 crossref_primary_10_3390_molecules25010016 crossref_primary_10_1002_cmdc_201800402 crossref_primary_10_1080_09546634_2022_2089616 crossref_primary_10_1016_j_phytochem_2022_113213 crossref_primary_10_1016_j_jconrel_2022_10_011 crossref_primary_10_1208_s12249_024_03003_5 crossref_primary_10_3389_fimmu_2024_1416842 crossref_primary_10_1002_jcp_29413 crossref_primary_10_3390_ph14111083 crossref_primary_10_1007_s13346_020_00852_y crossref_primary_10_1080_17435889_2024_2405455 crossref_primary_10_2147_IJN_S296726 crossref_primary_10_1016_j_carbpol_2019_115659
Cites_doi	10.1016/S1471-4906(02)00013-3 10.1016/j.apsb.2014.12.001 10.1016/j.brainresrev.2008.12.020 10.1111/bjd.12230 10.1088/0957-4484/21/28/285104 10.1111/j.1365-2133.1988.tb03204.x 10.1186/ar1917 10.4049/jimmunol.0802999 10.3390/molecules19055925 10.1038/jid.2009.59 10.1056/NEJMoa0810652 10.1016/j.bcp.2011.09.029 10.1067/mjd.2001.117047 10.1016/j.intimp.2016.08.021 10.4103/0973-1296.103650 10.1016/j.ejpb.2014.03.019 10.1111/j.0022-202X.2005.23672.x 10.1111/j.1600-065X.2008.00697.x 10.1016/j.jconrel.2011.12.016 10.1016/j.ijpharm.2014.06.001 10.1007/s10787-007-0013-x 10.1001/archdermatol.2012.370 10.1016/j.colsurfb.2012.08.038 10.1111/j.1365-4362.1996.tb03687.x 10.3389/fphar.2015.00219 10.1111/j.1365-4362.1992.tb04012.x 10.1016/j.fct.2010.05.003 10.1016/j.jaad.2002.12.002 10.1517/17425247.2014.938634 10.1016/j.jconrel.2013.05.020 10.1371/journal.pone.0067078 10.5012/bkcs.2014.35.8.2290 10.1074/jbc.M111883200 10.1615/CritRevTherDrugCarrierSyst.2013005268 10.1172/JCI1368 10.1016/j.jconrel.2016.10.004 10.5799/ahinjs.01.2014.02.0387 10.1016/j.ijpharm.2012.08.016 10.1111/j.1365-2249.1994.tb06244.x 10.1016/j.ejps.2016.10.025 10.1111/j.1365-2133.1980.tb05692.x
ContentType	Journal Article
Copyright	2017 Elsevier Inc. Copyright © 2017 Elsevier Inc. All rights reserved.
Copyright_xml	– notice: 2017 Elsevier Inc. – notice: Copyright © 2017 Elsevier Inc. All rights reserved.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.nano.2017.06.009
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1549-9642
EndPage	2262
ExternalDocumentID	28647592 10_1016_j_nano_2017_06_009 S1549963417301168 1_s2_0_S1549963417301168
Genre	Journal Article
GrantInformation_xml	– fundername: Ministry of AYUSH, Govt. of India grantid: Z.28015/121/2014-HPC(EMR)-AYUSH-C
GroupedDBID	--- --K --M .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 71M 8P~ AAAJQ AABXZ AAEDT AAEDW AAEPC AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABGSF ABMAC ABMZM ABUDA ABWVN ABXDB ABXRA ABZDS ACDAQ ACGFS ACIEU ACLOT ACNNM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADTZH ADUVX AEBSH AECPX AEHWI AEIPS AEKER AEUPX AEVXI AEZYN AFJKZ AFPUW AFRHN AFRZQ AFTJW AFXIZ AGEKW AGHFR AGUBO AGYEJ AHJVU AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BJAXD BKOJK BLXMC BNPGV CJTIS CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W JJJVA KOM LUGTX M41 MAGPM MO0 N9A O-L O9- OAUVE OD~ OGGZJ OO0 OZT P-8 P-9 P2P PC. Q38 ROL RPZ SDF SDG SEL SES SEW SPC SSH SSI SSM SSP SST SSU SSZ T5K Z5R ~G- ~HD AACTN AFKWA AJOXV AMFUW RIG AAIAV AATCM ABLVK ABYKQ AJBFU DOVZS LCYCR 9DU AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c462t-4e4be2fad008206a1e6d32fbe6903a58ddffc99ddb22c842f22698f4ec19d2d23
ISICitedReferencesCount	75
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000411954200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1549-9634 1549-9642
IngestDate	Mon Sep 29 06:37:23 EDT 2025 Wed Feb 19 02:42:31 EST 2025 Sat Nov 29 03:06:47 EST 2025 Tue Nov 18 20:36:47 EST 2025 Fri Feb 23 02:12:40 EST 2024 Sun Feb 23 10:18:49 EST 2025 Tue Oct 14 19:34:57 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	Inflammation Psoriasis Lipospheres Thymoquinone Imiquimod induced psoriatic plaque model Imiquimod induced psoriatic mice model
Language	English
License	Copyright © 2017 Elsevier Inc. All rights reserved.
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-c462t-4e4be2fad008206a1e6d32fbe6903a58ddffc99ddb22c842f22698f4ec19d2d23
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	28647592
PQID	1913830081
PQPubID	23479
PageCount	12
ParticipantIDs	proquest_miscellaneous_1913830081 pubmed_primary_28647592 crossref_primary_10_1016_j_nano_2017_06_009 crossref_citationtrail_10_1016_j_nano_2017_06_009 elsevier_sciencedirect_doi_10_1016_j_nano_2017_06_009 elsevier_clinicalkeyesjournals_1_s2_0_S1549963417301168 elsevier_clinicalkey_doi_10_1016_j_nano_2017_06_009
PublicationCentury	2000
PublicationDate	2017-10-01
PublicationDateYYYYMMDD	2017-10-01
PublicationDate_xml	– month: 10 year: 2017 text: 2017-10-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Nanomedicine
PublicationTitleAlternate	Nanomedicine
PublicationYear	2017
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Griffiths, Strober, van de Kerkhof, Ho, Fidelus-Gort, Yeilding (bb0040) 2010; 362 Maniar, Domb (bb0070) 1991 Hoyer, Dooms, Barron, Abbas (bb0200) 2008; 226 Avramoff, Khan, Ezra, Elgart, Hoffman, Domb (bb0060) 2012; 160 (bb0165) 2017 Lee, Shin, Jang, Lee (bb0145) 2016; 40 Singh, Ahmad, Akhter, Jain, Iqbal, Talegaonkar (bb0120) 2013; 102 Lassus (bb0025) 1980; 102 Cornell (bb0030) 1992; 31 Xing, Gauldie, Cox, Baumann, Jordana, Lei (bb0210) 1998; 101 Hwang, Han, Jeon, Seo, Oh, Cho (bb0140) 2014; 35 Doppalapudi, Jain, Chopra, Khan (bb0035) 2017; 96 Nasr, Ghorab, Abdelazem (bb0115) 2015; 5 Hsu, Wen (bb0150) 2002; 277 Kaplanski, Marin, Montero-Julian, Mantovani, Farnarier (bb0215) 2003; 24 Christopher Penney, Laurin, Zacharie (bb0185) 2004 Raut, Prabhu, Patravale (bb0010) 2013; 30 Ren, Torres (bb0205) 2009; 60 Zhang, Shen, Wu, Zhao, Feng (bb0160) 2014; 471 Kragballe, Beck, Søgaard (bb0045) 1988; 119 Lebwohl, Ali (bb0100) 2001; 45 Ettehadi, Greaves, Wallach, Aderka, Camp (bb0225) 1994; 96 Dwarampudi, Palaniswamy, Nithyanantham, Raghu (bb0090) 2012; 8 Yu, Ma, Lei, Li, Tan (bb0135) 2014; 88 Danielsen, Olsen, Wilsgaard, Furberg (bb0020) 2013; 168 Dokka, Cooper, Kelly, Hardee, Karras (bb0130) 2005; 124 Pradhan, Singh, Singh (bb0005) 2013; 170 Salmani, Asghar, Lv, Zhou (bb0105) 2014; 19 Sharma, Al-Omran, Parvathy (bb0190) 2007; 15 Woo, Kumar, Sethi, Tan (bb0085) 2012; 83 Gelfand, Wan, Duffin, Krueger, Kalb, Weisman (bb0050) 2012; 148 Domb, Avramoff, Pevzner (bb0075) 2010 Lebwohl, Menter, Koo, Feldman (bb0195) 2004; 50 Heo, Yoon, Kim, Ahn, Kang, Kang (bb0155) 2010; 48 Di Cesare, Di Meglio, Nestle (bb0180) 2009; 129 Gibbs (bb0015) 1996; 35 Gabay (bb0220) 2006; 8 Sun, Zhao, Hu (bb0230) 2013; 8 van der Fits, Mourits, Voerman, Kant, Boon, Laman (bb0170) 2009; 182 Ahmed Jawad, Ibraheem Azhar, Al-Hamdi Khalil (bb0095) 2014; 5 Blalock, Varela, Gowda, Tang, Chen, Mast (bb0175) 2001; 13 Jain, Doppalapudi, Domb, Khan (bb0065) 2016; 243 Hua (bb0055) 2015; 6 Sonawane, Harde, Katariya, Agrawal, Jain (bb0125) 2014; 11 Ganea, Fakayode, Losso, Van Nostrum, Sabliov, Warner (bb0080) 2010; 21 Khan, Aldouby, Avramoff, Domb (bb0110) 2012; 437 Gelfand (10.1016/j.nano.2017.06.009_bb0050) 2012; 148 Dwarampudi (10.1016/j.nano.2017.06.009_bb0090) 2012; 8 Raut (10.1016/j.nano.2017.06.009_bb0010) 2013; 30 Ahmed Jawad (10.1016/j.nano.2017.06.009_bb0095) 2014; 5 Ganea (10.1016/j.nano.2017.06.009_bb0080) 2010; 21 van der Fits (10.1016/j.nano.2017.06.009_bb0170) 2009; 182 Pradhan (10.1016/j.nano.2017.06.009_bb0005) 2013; 170 Hua (10.1016/j.nano.2017.06.009_bb0055) 2015; 6 Gabay (10.1016/j.nano.2017.06.009_bb0220) 2006; 8 Woo (10.1016/j.nano.2017.06.009_bb0085) 2012; 83 Doppalapudi (10.1016/j.nano.2017.06.009_bb0035) 2017; 96 Hsu (10.1016/j.nano.2017.06.009_bb0150) 2002; 277 Kaplanski (10.1016/j.nano.2017.06.009_bb0215) 2003; 24 Domb (10.1016/j.nano.2017.06.009_bb0075) 2010 Christopher Penney (10.1016/j.nano.2017.06.009_bb0185) 2004 Xing (10.1016/j.nano.2017.06.009_bb0210) 1998; 101 Jain (10.1016/j.nano.2017.06.009_bb0065) 2016; 243 Hoyer (10.1016/j.nano.2017.06.009_bb0200) 2008; 226 Avramoff (10.1016/j.nano.2017.06.009_bb0060) 2012; 160 Khan (10.1016/j.nano.2017.06.009_bb0110) 2012; 437 Danielsen (10.1016/j.nano.2017.06.009_bb0020) 2013; 168 Lebwohl (10.1016/j.nano.2017.06.009_bb0100) 2001; 45 Salmani (10.1016/j.nano.2017.06.009_bb0105) 2014; 19 Blalock (10.1016/j.nano.2017.06.009_bb0175) 2001; 13 Ettehadi (10.1016/j.nano.2017.06.009_bb0225) 1994; 96 Singh (10.1016/j.nano.2017.06.009_bb0120) 2013; 102 Sun (10.1016/j.nano.2017.06.009_bb0230) 2013; 8 Griffiths (10.1016/j.nano.2017.06.009_bb0040) 2010; 362 Lassus (10.1016/j.nano.2017.06.009_bb0025) 1980; 102 Cornell (10.1016/j.nano.2017.06.009_bb0030) 1992; 31 Sonawane (10.1016/j.nano.2017.06.009_bb0125) 2014; 11 Nasr (10.1016/j.nano.2017.06.009_bb0115) 2015; 5 Heo (10.1016/j.nano.2017.06.009_bb0155) 2010; 48 Lee (10.1016/j.nano.2017.06.009_bb0145) 2016; 40 Sharma (10.1016/j.nano.2017.06.009_bb0190) 2007; 15 Di Cesare (10.1016/j.nano.2017.06.009_bb0180) 2009; 129 Yu (10.1016/j.nano.2017.06.009_bb0135) 2014; 88 Kragballe (10.1016/j.nano.2017.06.009_bb0045) 1988; 119 Ren (10.1016/j.nano.2017.06.009_bb0205) 2009; 60 Lebwohl (10.1016/j.nano.2017.06.009_bb0195) 2004; 50 Maniar (10.1016/j.nano.2017.06.009_bb0070) 1991 Hwang (10.1016/j.nano.2017.06.009_bb0140) 2014; 35 (10.1016/j.nano.2017.06.009_bb0165) 2017 Dokka (10.1016/j.nano.2017.06.009_bb0130) 2005; 124 Gibbs (10.1016/j.nano.2017.06.009_bb0015) 1996; 35 Zhang (10.1016/j.nano.2017.06.009_bb0160) 2014; 471
References_xml	– volume: 102 start-page: 195 year: 1980 end-page: 202 ident: bb0025 article-title: Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359) publication-title: Br J Dermatol – volume: 148 start-page: 487 year: 2012 end-page: 494 ident: bb0050 article-title: Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting publication-title: Arch Dermatol – volume: 83 start-page: 443 year: 2012 end-page: 451 ident: bb0085 article-title: Thymoquinone: potential cure for inflammatory disorders and cancer publication-title: Biochem Pharmacol – volume: 96 start-page: 146 year: 1994 end-page: 151 ident: bb0225 article-title: Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions publication-title: Clin Exp Immunol – volume: 182 start-page: 5836 year: 2009 end-page: 5845 ident: bb0170 article-title: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis publication-title: J Immunol – volume: 24 start-page: 25 year: 2003 end-page: 29 ident: bb0215 article-title: IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation publication-title: Trends Immunol – volume: 13 start-page: 35 year: 2001 end-page: 36 ident: bb0175 article-title: Ischemic skin wound healing models in rats publication-title: Wounds – volume: 362 start-page: 118 year: 2010 end-page: 128 ident: bb0040 article-title: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis publication-title: N Engl J Med – year: 2010 ident: bb0075 article-title: Pro-nanodispersion for the delivery of cyclosporin – volume: 88 start-page: 92 year: 2014 end-page: 103 ident: bb0135 article-title: In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties publication-title: Eur J Pharm Biopharm – volume: 437 start-page: 275 year: 2012 end-page: 276 ident: bb0110 article-title: Cyclosporin nanosphere formulation for ophthalmic administration publication-title: Int J Pharm – volume: 8 start-page: 1 year: 2006 end-page: 6 ident: bb0220 article-title: Interleukin-6 and chronic inflammation publication-title: Arthritis Res Ther – volume: 124 start-page: 971 year: 2005 end-page: 975 ident: bb0130 article-title: Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin publication-title: J Invest Dermatol – year: 2004 ident: bb0185 article-title: Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis – volume: 31 start-page: 38 year: 1992 end-page: 40 ident: bb0030 article-title: Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay publication-title: Int J Dermatol – volume: 160 start-page: 401 year: 2012 end-page: 406 ident: bb0060 article-title: Cyclosporin pro-dispersion liposphere formulation publication-title: J Control Release – volume: 5 start-page: 186 year: 2014 end-page: 193 ident: bb0095 article-title: Evaluation of efficacy, safety and antioxidant effect of publication-title: J Clin Exp Invest – volume: 471 start-page: 449 year: 2014 end-page: 452 ident: bb0160 article-title: Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy publication-title: Int J Pharm – volume: 19 start-page: 5925 year: 2014 end-page: 5939 ident: bb0105 article-title: Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light publication-title: Molecules – volume: 11 start-page: 1833 year: 2014 end-page: 1847 ident: bb0125 article-title: Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis publication-title: Expert Opin Drug Deliv – volume: 35 start-page: 633 year: 1996 end-page: 639 ident: bb0015 article-title: Skin disease and socioeconomic conditions in rural Africa: Tanzania publication-title: Int J Dermatol – volume: 40 start-page: 146 year: 2016 end-page: 155 ident: bb0145 article-title: Cnidilide, an alkylphthalide isolated from the roots of Cnidium officinale, suppresses LPS-induced NO, PGE 2, IL-1β, IL-6 and TNF-α production by AP-1 and NF-κB inactivation in RAW 264.7 macrophages publication-title: Int Immunopharmacol – volume: 48 start-page: 2045 year: 2010 end-page: 2051 ident: bb0155 article-title: Evaluation of anti-inflammatory effect of fucoxanthin isolated from brown algae in lipopolysaccharide-stimulated RAW 264.7 macrophages publication-title: Food Chem Toxicol – volume: 8 start-page: e67078 year: 2013 ident: bb0230 article-title: Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice publication-title: PLoS One – volume: 96 start-page: 515 year: 2017 end-page: 529 ident: bb0035 article-title: Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis publication-title: Eur J Pharm Sci – volume: 21 start-page: 1 year: 2010 end-page: 10 ident: bb0080 article-title: Delivery of phytochemical thymoquinone using molecular micelle modified poly (D, L lactide-co-glycolide)(PLGA) nanoparticles publication-title: Nanotechnology – volume: 119 start-page: 223 year: 1988 end-page: 230 ident: bb0045 article-title: Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study publication-title: Br J Dermatol – volume: 60 start-page: 57 year: 2009 end-page: 64 ident: bb0205 article-title: Role of interleukin-1β during pain and inflammation publication-title: Brain Res Rev – volume: 243 start-page: 132 year: 2016 end-page: 145 ident: bb0065 article-title: Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis publication-title: J Control Release – volume: 15 start-page: 252 year: 2007 end-page: 259 ident: bb0190 article-title: Role of nitric oxide in inflammatory diseases publication-title: Inflammopharmacology – volume: 129 start-page: 1339 year: 2009 end-page: 1350 ident: bb0180 article-title: The IL-23/Th17 axis in the immunopathogenesis of psoriasis publication-title: J Invest Dermatol – volume: 30 start-page: 183 year: 2013 end-page: 216 ident: bb0010 article-title: Psoriasis clinical implications and treatment: a review publication-title: Crit Rev Ther Drug Carrier Syst – volume: 6 start-page: 1 year: 2015 end-page: 5 ident: bb0055 article-title: Lipid-based nano-delivery systems for skin delivery of drugs and bioactives publication-title: Front Pharmacol – volume: 102 start-page: 822 year: 2013 end-page: 832 ident: bb0120 article-title: Nanocarrier based formulation of thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies publication-title: Colloids Surf B Biointerfaces – volume: 45 start-page: 649 year: 2001 end-page: 664 ident: bb0100 article-title: Treatment of psoriasis. Part 2. Systemic therapies publication-title: J Am Acad Dermatol – volume: 168 start-page: 1303 year: 2013 end-page: 1310 ident: bb0020 article-title: Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort publication-title: Br J Dermatol – year: 1991 ident: bb0070 article-title: Lipospheres for controlled delivery of substances – volume: 5 start-page: 79 year: 2015 end-page: 88 ident: bb0115 article-title: In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting publication-title: Acta Pharm Sin B – volume: 50 start-page: 416 year: 2004 end-page: 430 ident: bb0195 article-title: Combination therapy to treat moderate to severe psoriasis publication-title: J Am Acad Dermatol – volume: 226 start-page: 19 year: 2008 end-page: 28 ident: bb0200 article-title: Interleukin-2 in the development and control of inflammatory disease publication-title: Immunol Rev – volume: 170 start-page: 380 year: 2013 end-page: 395 ident: bb0005 article-title: Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches publication-title: J Control Release – volume: 35 start-page: 2291 year: 2014 ident: bb0140 article-title: Recombinant human epidermal growth factor (rhEGF)-loaded solid lipid nanoparticles: fabrication and their skin accumulation properties for topical rhEGF delivery publication-title: Bull Korean Chem Soc – volume: 101 start-page: 311 year: 1998 end-page: 320 ident: bb0210 article-title: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses publication-title: J Clin Investig – volume: 8 start-page: 268 year: 2012 end-page: 272 ident: bb0090 article-title: Antipsoriatic activity and cytotoxicity of ethanolic extract of publication-title: Pharmacogn Mag – volume: 277 start-page: 22131 year: 2002 end-page: 22139 ident: bb0150 article-title: Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression publication-title: J Biol Chem – year: 2017 ident: bb0165 article-title: About psoriasis – volume: 24 start-page: 25 year: 2003 ident: 10.1016/j.nano.2017.06.009_bb0215 article-title: IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation publication-title: Trends Immunol doi: 10.1016/S1471-4906(02)00013-3 – volume: 5 start-page: 79 year: 2015 ident: 10.1016/j.nano.2017.06.009_bb0115 article-title: In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2014.12.001 – volume: 60 start-page: 57 year: 2009 ident: 10.1016/j.nano.2017.06.009_bb0205 article-title: Role of interleukin-1β during pain and inflammation publication-title: Brain Res Rev doi: 10.1016/j.brainresrev.2008.12.020 – volume: 168 start-page: 1303 year: 2013 ident: 10.1016/j.nano.2017.06.009_bb0020 article-title: Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort publication-title: Br J Dermatol doi: 10.1111/bjd.12230 – volume: 21 start-page: 1 year: 2010 ident: 10.1016/j.nano.2017.06.009_bb0080 article-title: Delivery of phytochemical thymoquinone using molecular micelle modified poly (D, L lactide-co-glycolide)(PLGA) nanoparticles publication-title: Nanotechnology doi: 10.1088/0957-4484/21/28/285104 – volume: 119 start-page: 223 year: 1988 ident: 10.1016/j.nano.2017.06.009_bb0045 article-title: Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.1988.tb03204.x – volume: 8 start-page: 1 year: 2006 ident: 10.1016/j.nano.2017.06.009_bb0220 article-title: Interleukin-6 and chronic inflammation publication-title: Arthritis Res Ther doi: 10.1186/ar1917 – year: 2004 ident: 10.1016/j.nano.2017.06.009_bb0185 – volume: 182 start-page: 5836 year: 2009 ident: 10.1016/j.nano.2017.06.009_bb0170 article-title: Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis publication-title: J Immunol doi: 10.4049/jimmunol.0802999 – volume: 19 start-page: 5925 year: 2014 ident: 10.1016/j.nano.2017.06.009_bb0105 article-title: Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light publication-title: Molecules doi: 10.3390/molecules19055925 – volume: 129 start-page: 1339 year: 2009 ident: 10.1016/j.nano.2017.06.009_bb0180 article-title: The IL-23/Th17 axis in the immunopathogenesis of psoriasis publication-title: J Invest Dermatol doi: 10.1038/jid.2009.59 – volume: 362 start-page: 118 year: 2010 ident: 10.1016/j.nano.2017.06.009_bb0040 article-title: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis publication-title: N Engl J Med doi: 10.1056/NEJMoa0810652 – volume: 83 start-page: 443 year: 2012 ident: 10.1016/j.nano.2017.06.009_bb0085 article-title: Thymoquinone: potential cure for inflammatory disorders and cancer publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2011.09.029 – volume: 45 start-page: 649 year: 2001 ident: 10.1016/j.nano.2017.06.009_bb0100 article-title: Treatment of psoriasis. Part 2. Systemic therapies publication-title: J Am Acad Dermatol doi: 10.1067/mjd.2001.117047 – volume: 40 start-page: 146 year: 2016 ident: 10.1016/j.nano.2017.06.009_bb0145 article-title: Cnidilide, an alkylphthalide isolated from the roots of Cnidium officinale, suppresses LPS-induced NO, PGE 2, IL-1β, IL-6 and TNF-α production by AP-1 and NF-κB inactivation in RAW 264.7 macrophages publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2016.08.021 – volume: 8 start-page: 268 year: 2012 ident: 10.1016/j.nano.2017.06.009_bb0090 article-title: Antipsoriatic activity and cytotoxicity of ethanolic extract of Nigella sativa seeds publication-title: Pharmacogn Mag doi: 10.4103/0973-1296.103650 – volume: 88 start-page: 92 year: 2014 ident: 10.1016/j.nano.2017.06.009_bb0135 article-title: In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2014.03.019 – volume: 124 start-page: 971 year: 2005 ident: 10.1016/j.nano.2017.06.009_bb0130 article-title: Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin publication-title: J Invest Dermatol doi: 10.1111/j.0022-202X.2005.23672.x – volume: 226 start-page: 19 year: 2008 ident: 10.1016/j.nano.2017.06.009_bb0200 article-title: Interleukin-2 in the development and control of inflammatory disease publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2008.00697.x – volume: 160 start-page: 401 year: 2012 ident: 10.1016/j.nano.2017.06.009_bb0060 article-title: Cyclosporin pro-dispersion liposphere formulation publication-title: J Control Release doi: 10.1016/j.jconrel.2011.12.016 – volume: 471 start-page: 449 year: 2014 ident: 10.1016/j.nano.2017.06.009_bb0160 article-title: Comparison of ethosomes and liposomes for skin delivery of psoralen for psoriasis therapy publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2014.06.001 – year: 2017 ident: 10.1016/j.nano.2017.06.009_bb0165 – volume: 15 start-page: 252 year: 2007 ident: 10.1016/j.nano.2017.06.009_bb0190 article-title: Role of nitric oxide in inflammatory diseases publication-title: Inflammopharmacology doi: 10.1007/s10787-007-0013-x – volume: 148 start-page: 487 year: 2012 ident: 10.1016/j.nano.2017.06.009_bb0050 article-title: Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting publication-title: Arch Dermatol doi: 10.1001/archdermatol.2012.370 – volume: 102 start-page: 822 year: 2013 ident: 10.1016/j.nano.2017.06.009_bb0120 article-title: Nanocarrier based formulation of thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies publication-title: Colloids Surf B Biointerfaces doi: 10.1016/j.colsurfb.2012.08.038 – volume: 35 start-page: 633 year: 1996 ident: 10.1016/j.nano.2017.06.009_bb0015 article-title: Skin disease and socioeconomic conditions in rural Africa: Tanzania publication-title: Int J Dermatol doi: 10.1111/j.1365-4362.1996.tb03687.x – volume: 6 start-page: 1 year: 2015 ident: 10.1016/j.nano.2017.06.009_bb0055 article-title: Lipid-based nano-delivery systems for skin delivery of drugs and bioactives publication-title: Front Pharmacol doi: 10.3389/fphar.2015.00219 – volume: 31 start-page: 38 year: 1992 ident: 10.1016/j.nano.2017.06.009_bb0030 article-title: Clinical trials of topical corticosteroids in psoriasis: correlations with the vasoconstrictor assay publication-title: Int J Dermatol doi: 10.1111/j.1365-4362.1992.tb04012.x – volume: 13 start-page: 35 year: 2001 ident: 10.1016/j.nano.2017.06.009_bb0175 article-title: Ischemic skin wound healing models in rats publication-title: Wounds – volume: 48 start-page: 2045 year: 2010 ident: 10.1016/j.nano.2017.06.009_bb0155 article-title: Evaluation of anti-inflammatory effect of fucoxanthin isolated from brown algae in lipopolysaccharide-stimulated RAW 264.7 macrophages publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2010.05.003 – year: 1991 ident: 10.1016/j.nano.2017.06.009_bb0070 – volume: 50 start-page: 416 year: 2004 ident: 10.1016/j.nano.2017.06.009_bb0195 article-title: Combination therapy to treat moderate to severe psoriasis publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2002.12.002 – year: 2010 ident: 10.1016/j.nano.2017.06.009_bb0075 – volume: 11 start-page: 1833 year: 2014 ident: 10.1016/j.nano.2017.06.009_bb0125 article-title: Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis publication-title: Expert Opin Drug Deliv doi: 10.1517/17425247.2014.938634 – volume: 170 start-page: 380 year: 2013 ident: 10.1016/j.nano.2017.06.009_bb0005 article-title: Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches publication-title: J Control Release doi: 10.1016/j.jconrel.2013.05.020 – volume: 8 start-page: e67078 year: 2013 ident: 10.1016/j.nano.2017.06.009_bb0230 article-title: Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice publication-title: PLoS One doi: 10.1371/journal.pone.0067078 – volume: 35 start-page: 2291 year: 2014 ident: 10.1016/j.nano.2017.06.009_bb0140 article-title: Recombinant human epidermal growth factor (rhEGF)-loaded solid lipid nanoparticles: fabrication and their skin accumulation properties for topical rhEGF delivery publication-title: Bull Korean Chem Soc doi: 10.5012/bkcs.2014.35.8.2290 – volume: 277 start-page: 22131 year: 2002 ident: 10.1016/j.nano.2017.06.009_bb0150 article-title: Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression publication-title: J Biol Chem doi: 10.1074/jbc.M111883200 – volume: 30 start-page: 183 year: 2013 ident: 10.1016/j.nano.2017.06.009_bb0010 article-title: Psoriasis clinical implications and treatment: a review publication-title: Crit Rev Ther Drug Carrier Syst doi: 10.1615/CritRevTherDrugCarrierSyst.2013005268 – volume: 101 start-page: 311 year: 1998 ident: 10.1016/j.nano.2017.06.009_bb0210 article-title: IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses publication-title: J Clin Investig doi: 10.1172/JCI1368 – volume: 243 start-page: 132 year: 2016 ident: 10.1016/j.nano.2017.06.009_bb0065 article-title: Tacrolimus and curcumin co-loaded liposphere gel: synergistic combination towards management of psoriasis publication-title: J Control Release doi: 10.1016/j.jconrel.2016.10.004 – volume: 5 start-page: 186 year: 2014 ident: 10.1016/j.nano.2017.06.009_bb0095 article-title: Evaluation of efficacy, safety and antioxidant effect of Nigella sativa in patients with psoriasis: a randomized clinical trial publication-title: J Clin Exp Invest doi: 10.5799/ahinjs.01.2014.02.0387 – volume: 437 start-page: 275 year: 2012 ident: 10.1016/j.nano.2017.06.009_bb0110 article-title: Cyclosporin nanosphere formulation for ophthalmic administration publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2012.08.016 – volume: 96 start-page: 146 year: 1994 ident: 10.1016/j.nano.2017.06.009_bb0225 article-title: Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1994.tb06244.x – volume: 96 start-page: 515 year: 2017 ident: 10.1016/j.nano.2017.06.009_bb0035 article-title: Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis publication-title: Eur J Pharm Sci doi: 10.1016/j.ejps.2016.10.025 – volume: 102 start-page: 195 year: 1980 ident: 10.1016/j.nano.2017.06.009_bb0025 article-title: Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359) publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.1980.tb05692.x
SSID	ssj0037009
Score	2.492148
Snippet	Thymoquinone (TMQ) is reported with good anti-psoriatic activity; however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature of TMQ... Abstract Thymoquinone (TMQ) is reported with good anti-psoriatic activity however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature...
SourceID	proquest pubmed crossref elsevier
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	2251
SubjectTerms	Administration, Topical Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - pharmacokinetics Anti-Inflammatory Agents - therapeutic use Benzoquinones - administration & dosage Benzoquinones - pharmacokinetics Benzoquinones - therapeutic use Imiquimod induced psoriatic plaque model Inflammation Interleukin-17 - analysis Interleukin-2 - analysis Interleukin-6 - analysis Internal Medicine Liposomes Lipospheres Male Mice Mice, Inbred BALB C Psoriasis Psoriasis - drug therapy RAW 264.7 Cells Skin - drug effects Skin - pathology Skin Absorption Thymoquinone Tumor Necrosis Factor-alpha - analysis
Title	Liposphere mediated topical delivery of thymoquinone in the treatment of psoriasis
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S1549963417301168 https://www.clinicalkey.es/playcontent/1-s2.0-S1549963417301168 https://dx.doi.org/10.1016/j.nano.2017.06.009 https://www.ncbi.nlm.nih.gov/pubmed/28647592 https://www.proquest.com/docview/1913830081
Volume	13
WOSCitedRecordID	wos000411954200016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1549-9642 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0037009 issn: 1549-9634 databaseCode: AIEXJ dateStart: 20050301 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DiFeEHfKZQoSbygocdLEfhwwBBNMiG1S3ywndkRKlISmmcbv4A9zHF-abWxcJKTKaqI4dnw-H59jfz5G6HmQESw4FT6nUjko89wnFBxXwpMskzH8cDEcNpEeHJDFgn6aTH7YvTAnVVrX5PSUtv9V1HAPhK22zv6FuN1L4Qb8B6FDCmKH9I8E_6Fsm04FC5B6W4gyKddNq5djZKV4GN81MwDc_m99Cf6_tGzHDe18IEI3UN2u7MYGLGjj5vx6_D63gQiWYNU7ZduA1yzURMXApZX1V2XWutnnV32Vcc0MOlbn8K7c-PCmaVte8bYXA9PgsKzFl348OwEjnuW5mSkzu23mDKtThYXzoefrmQQ5vhefVc3RCILpWM9iE6ZWmkut0i-MB3pqYvmyhsZRPL50CNYa0M3o5ziJh6oGqlLhoPQSsoW2cTqnZIq2d9_vLfbtAB-lwcAccl9h9mJp2uD5ki6zdy7zZwa75ugWumkcEm9XA-k2msj6Drr-0Yj4Lvq8wZNn8eQZPHkWT15TeGM8eWUN19JzeFIPODzdQ8dv945ev_PNQRx-Hid47ceq0-KCi8FgTHgoExHhIpMJDSI-J0IURU6pEBnGOYHeDfKgpIhlHlKBBY7uo6kq_CHywrwoQhHHaRoo211yKXieQQquNCZJMkOhbS6Wmyj16rCUilk64pKpJmaqidnAyaQz9MLlaXWMliufjqwUmN19DOMlA8hcmSv9VS7ZmZ7fsZB1mAXsAoxmaO5yGqtWW6u_LfGZhQgDla_W8Xgtmx5KomFEImXMz9ADjR333dCGKoInfvSPpT5GNzbd-Amarle9fIqu5SfrslvtoK10QXZMf_gJMHnfPQ
linkProvider	Elsevier
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Liposphere+mediated+topical+delivery+of+thymoquinone+in+the+treatment+of+psoriasis&rft.jtitle=Nanomedicine&rft.au=Jain%2C+Anjali&rft.au=Pooladanda%2C+Venkatesh&rft.au=Bulbake%2C+Upendra&rft.au=Doppalapudi%2C+Sindhu&rft.date=2017-10-01&rft.pub=Elsevier+Inc&rft.issn=1549-9634&rft.eissn=1549-9642&rft.volume=13&rft.issue=7&rft.spage=2251&rft.epage=2262&rft_id=info:doi/10.1016%2Fj.nano.2017.06.009&rft.externalDocID=S1549963417301168
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-9634&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-9634&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-9634&client=summon